<button id="eiezk"><video id="eiezk"></video></button>

產(chǎn)品名稱

YM 155

產(chǎn)品貨號

Axon 1639 CAS [781661-94-7] MF C20H19BrN4O3MW 443.29 Purity: 98% Soluble in DMSO Description Small molecule survivin suppresant or inhibitor; YM155 suppressed expression of survivin and induced apoptosis in p53-deficient human HRPC cell lines at 10 nmol/L References Certificates Categories Extra info A Kita et al. Survivin suppressant: a promising target for cancer therapy and pharmacological profiles of YM155. Nippon Yakurigaku Zasshi 2010, 136(4), 198-203. ? T Iwasa et al. Marked anti-tumour activity of the combination of YM155, a novel survivin suppressant, and platinum-based drugs. Br. J. Cancer 2010, 103(1),36-42. ? T Nakahara et al. YM155, a Novel Small-Molecule Survivin Suppressant, Induces Regression of Established Human Hormone-Refractory Prostate Tumor Xenografts. Cancer Res. 2007, 67, 8014-8021. ? R Gonzalez et al. A phase II study of YM155, a novel survivin suppressant, administered by 168 hour continuous infusion in patients with unresectable stage III or stage IV melanoma.?J. Clin. Oncol. 2007,?25(18S), 8538. ? T Satoh et al. Phase I Study of YM155, a Novel Survivin Suppressant, in Patients with Advanced Solid Tumors. Clin. Cancer Res. 2009, 15, 3872. Certificate of Analysis Material Safety Data Sheet Apoptosis Cell Cycle Regulation Cell Signaling & Oncology Ubiquitin IAP Survivin suppressant Chemical name 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9-dihydro-1H-naphtho[2,3-d]imidazol-3-ium bromide Parent CAS No. [N.A.] Order Size Unit Price Stock 5 mg €95.00 In Stock

產(chǎn)品價(jià)格

現(xiàn)貨詢價(jià)，電話：010-67529703

產(chǎn)品規(guī)格

產(chǎn)品品牌

axonmedchem

產(chǎn)品概述

產(chǎn)品詳情

YM 155

Based on 8 reference(s) in Google Scholar 9 10 8

Axon 1639

CAS [781661-94-7]

MF C20H19BrN4O3
MW 443.29

Purity: 98%
Soluble in DMSO

YM 155

Description

Small molecule survivin suppresant or inhibitor; YM155 suppressed expression of survivin and induced apoptosis in p53-deficient human HRPC cell lines at 10 nmol/L

A Kita et al. Survivin suppressant: a promising target for cancer therapy and pharmacological profiles of YM155. Nippon Yakurigaku Zasshi 2010, 136(4), 198-203.

T Iwasa et al. Marked anti-tumour activity of the combination of YM155, a novel survivin suppressant, and platinum-based drugs. Br. J. Cancer 2010, 103(1),36-42.

T Nakahara et al. YM155, a Novel Small-Molecule Survivin Suppressant, Induces Regression of Established Human Hormone-Refractory Prostate Tumor Xenografts. Cancer Res. 2007, 67, 8014-8021.

R Gonzalez et al. A phase II study of YM155, a novel survivin suppressant, administered by 168 hour continuous infusion in patients with unresectable stage III or stage IV melanoma.?J. Clin. Oncol. 2007,?25(18S), 8538.

T Satoh et al. Phase I Study of YM155, a Novel Survivin Suppressant, in Patients with Advanced Solid Tumors. Clin. Cancer Res. 2009, 15, 3872.

Certificate of Analysis
Material Safety Data Sheet

Apoptosis Cell Cycle Regulation Cell Signaling & Oncology Ubiquitin IAP

Survivin suppressant

Chemical name

1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9-dihydro-1H-naphtho[2,3-d]imidazol-3-ium bromide

Parent CAS No.

[N.A.]

產(chǎn)品資料

<button id="eiezk"><video id="eiezk"></video></button>